Abstract 485P
Background
Gliomas are primary tumors originating in the brain parenchyma known for their aggressive and diffusive behavior. The diagnosis is based on pathological anatomy that consists of morphological, immunohistochemical and molecular analysis. Simulating the behavior of gliomas in mathematical modeling is a powerful tool in evaluating tumor growth, as well as assisting in therapeutic decision-making.
Methods
We propose a mathematical model of continuous evolution of glioma that seeks to predict its spatio-temporal evolution through interactions of cell populations (concentration (C) of cancer cells “C_C” and dead cells “C_m”) with microenvironment (Mev) nutrients (nutrient C “ C_n”). As it is a complex phenomenon, this model takes into account the process of cell division (proliferation), death and motility. The cell division rate is assumed to follow a logistic model where the proliferation coefficient “r(C_C, C_n)” will be evaluated depending on the C of diseased cells (C_C) and nutrients (oxygen - C_n). The motility coefficient (D_c) and the Mev support capacity (C_Tmax) vary spatially as presented in the literature. For the cell death rate, it was considered that this is a function of the nutrient concentration “k_cm (C_n)” in the Mev. The non-linear system of partial differential equations, for the variables Cc (t,x), Cm (t,x), and Cn (t,x),was solved by the Method of Lines (MOL).
Results
In table we present some results for the average tumor cell population (Nc - Cells) as a function of time (in the limit cases when kn and kcm are very small and a = 0, 62.5) and comparisons with literature data. Nc - Cells for a = 0 and a = 62.5. Table: 485P
t (days) | a = 0 | a = 62.5 | ||||
Present | Ref. [1] | Ref. [2] | Present | Ref. [1] | Ref. [2] | |
1080 | 1710 | — | 1752 | 3116 | 3134 | 3126 |
Conclusions
Results for C, Nc - Cells, average tumor size and growth rate were obtained and compared to those available in the literature, showing that the presente model, with contributions that make it more rigorous and complex, appears to be physically coherent and capable of evaluating the spatio-temporal tumor growth.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
576P - Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Presenter: Jifang Gong
Session: Poster session 16
577P - Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Presenter: Eric Christenson
Session: Poster session 16
579P - Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study
Presenter: Paolo Nuciforo
Session: Poster session 16
581P - mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials
Presenter: Marco Germani
Session: Poster session 16
582P - Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study
Presenter: debora basile
Session: Poster session 16
583P - COMPReS study: Multiomic profiling reveals organ-specific differences in metastases and identifies novel predictive biomarkers in relapsed localized colon cancer
Presenter: Blanca García-Mico
Session: Poster session 16
584P - Genomic and transcriptomic characterization of peritoneal, lung and liver metastases of colorectal carcinoma reveals site-specific differences
Presenter: Nerma Crnovrsanin
Session: Poster session 16
585P - Prospective validation of the metastatic colon cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Presenter: Norbert Marschner
Session: Poster session 16